• Proceedings of the Korean Vacuum Society Conference
• /
• 2014.02a
• /
• pp.432.1-432.1
• /
• 2014

Hydroxyapatite (Ca10(PO4)6(OH)2) is known as the main inorganic component of mature mammalian bones and teeth. Because of its biocompatibility, hydroxyapatite has attracted much attention due to its potential applications in many biomedical researches. Here, we tested a therapeutic potential for the use of hydroxyapatite as an anticancer drug delivery vector. We prepared various types of hydroxyapatite having different chemical contents and morphologies using hydrothermal synthesis. The capability of hydroxyapatite as drug delivery materials was examined by adsorption kinetics of 5-fluorouracil molecules, a common anticancer drug, in phosphate buffered saline. We find that hydroxyapatite with smaller crystal size and higher phosphate contents shows improved adsorption property. Given that hydroxyapatite provides a scaffold for bone regeneration, these results highlight a potential use of hydroxyapatite in therapies aimed at osteosarcoma.

• Tuberculosis and Respiratory Diseases
• /
• v.59 no.5
• /
• pp.536-540
• /
• 2005

The combination of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) has recently been shown to be beneficial in advanced colorectal and gastric cancers. The side effects of this regimen include neutropenia, diarrhea and neurosensory toxicity. However, case reports on the pulmonary toxicities of this regimen are very limited. Especially, the development of pulmonary fibrosis has never been cited in the literature. Herein is reported the case of a patient treated with oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in whom pulmonary fibrosis developed, but which improved after steroid pulse therapy.

• Journal of the Korean Society of Safety
• /
• v.24 no.4
• /
• pp.47-52
• /
• 2009

This study has been to examine the occupational exposure levels of Fluorouracil (5-FU) in a hospital and to investigate the most effective cleaning reagent for control. Fluorouracil is one of the cytotoxic drugs which are therapeutic agents used to treat cancer. The health practitioners working in the cytotoxic work room and oncology ward areas are exposed to adverse health risks like cytogenetic and DNA damage from cytotoxic drugs exposure by frequent skin contact from contaminated surfaces. Four kinds of cleaning reagents has been examined to degrade the 5-FU. It was found that 5-FU was only degraded soon after the reaction in 0.5%(w/v) NaClO solution. Therefore, 0.5%(w/v) NaClO solution has been chosen to decompose any residues on the contamination surfaces. A substantial level of contamination was found on the surfaces of cytotoxic work room and oncology ward areas. The contamination ranges of the surfaces in cytotoxic work room and oncology ward areas were from 2.0 to $13.8{\mu}g/m^2$ and 5.39 to $11.53{\mu}g/m^2$ respectively. Consequently, regulation of the occupational exposure limit, procedure of special cleaning, and the use of personal protective equipment are recommended during the manipulation and administration of the drugs to avoid skin contamination from cytotoxic drugs like 5-FU.

• Journal of Pharmaceutical Investigation
• /
• v.16 no.3
• /
• pp.101-105
• /
• 1986

The changes of water absorption and surface area of polydimethylsiloxane-5-fluorouracil devices containing different water soluble additives such as sodium chloride, glycerine, poly-propylene glycol(PPG 400), and polyethylene oxide(PEO 400, 400 and 2000) were investigated. It was confirmed that carriers controlled water absorption and swelling of the devices in the aqueous solutions. The water absorption and the swelling were affected by the osmotic pressure and ionic strength of the aqueous solutions.

• Bulletin of the Korean Chemical Society
• /
• v.1 no.4
• /
• pp.121-123
• /
• 1980

$C_4$-Photocycloaddition of 5,7-dimethoxycoumarin(DMC) to 5-fluorouracil(5-FU) was studied in frozen aqueous solution. The major photoproduct was diagnosed and isolated by TLC and column chromatography. The structure of isolated photoproduct was identified as a $C_4$-cycloaddition product of DMC and 5-FU by the characteristics of its UV, IR, NMR, mass spectra, elemental analysis, and photosplitting.

• Bulletin of the Korean Chemical Society
• /
• v.7 no.3
• /
• pp.228-230
• /
• 1986

Diacetylene compound, 1,4-diphenyl-1,3-butadiyne, was photolyzed with 5-fluorouracil as a model reaction of the phototoxic conjugated poly-ynes with DNA or RNA and obtained a [2 + 2] photocycloadduct. The structure of the photoadduct was determined by spectral methods and compared with the [2 + 2] photoadducts of 1,4-diphenyl-1,3-butadiyne with tetramethylethylene and dimethyl fumarate.

• Radiation Oncology Journal
• /
• v.3 no.2
• /
• pp.87-93
• /
• 1985

The interaction of radiation and 5-Fluorouracil (5-FU) on mouse jejunal crypt cells was studied using the microcolony survival assay. 150mg/kg of 5-FU was injected intraperitoneally 15 minutes before irradiation and 6 hours after irradiation. Jejunal crypt cells of mouse survived more when 5-FU was given 15 minutes before irradiation than giving it 6 hours after irradiation. The mean lethal doses (Do) of each of irradiation alone group, 5-FU injection group of 15 minutes preceding irradiation, and 5-FU injection group of 6 hours post irradiation were, 135, 135, and 114 rad respectively. The dose effect factor (DEF) of each of 5-FU injection groups of 15 minutes preceding irradiation and of 6 hours post irradiation were 1.13 and 1.27

• Maxillofacial Plastic and Reconstructive Surgery
• /
• v.20 no.2
• /
• pp.158-165
• /
• 1998

This study was undertaken to observe the effects of the antineoplastic agent, 5-Fluorouracil(5 FU) on the hair in Sprague-Dawley white rats. Twenty four sprague-Dawley strain white rats, each weighing about 150-200 grams were used and divided into control and experimental groups. In the experimental group, eighteen rats were injected intraperitonially with 60 mg of 5-FU per killogram body weight with one time per two days, Six rats were injected with 0.5 cc of normal saline solution intraperitoneally as a placebo on this control group. Rats were serially sacrificed on the first, third, fifth, seventh, tenth and fourteenth day after 2 times of injection of 5-FU and saline. The hair were obtained and observed SEM. After examination and comparision of all specimens, the results of this study were as follows: 1. In the control group, the scale and cuticle of hair was observed smooth surface and equal interval 2. In the experimental group, the first day, scale change was seen from body of hair and crack was seen. from fifth day, and irregular scale and cuticle of hair was seen from 10, 14 days 3. The apperance of root of hair was not almost change From above results, 5-Fluorouracil was more effective on the hair body. The change was begun from first day and crack of scale was seen from fifth day and irregular scale and cuticle of hair was seen from 10,14 days. The.

• Korean Journal of Clinical Pharmacy
• /
• v.14 no.2
• /
• pp.61-70
• /
• 2004

Heptaplatin is a new platinum derivative with antitumor activity against gastric cancer. Preclinical studies showed that it is less toxic than other platinum analogues. The purpose of this study is to evaluate the efficacy and toxicity of the combination therapy of heptaplatin and 5-fluorouracil in Korean advanced gastric cancer patients. This study was investigated retrospectively. The patients group consisted of 65 advanced gastric cancer patients with no prior radiotherapy. All patients received heptaplatin $400\;mg/m^2$ by 2-3 hour infusion on Day 1 and 5-FU $1000\;mg/m^2by 12-24 hour continuous infusion for 5 days. After the first cycle, subsequent doses were adjusted according to the toxicity. Courses were repeated every 28 days. As results, objective response occurred in 16 patients $(24.6\%)$. Two were complete and 14 were partial response. Median progression free survival was 32 weeks with $29\%$ of patients progression free at 1 year. The most common hematologic toxicity was anemia. Grade 3 or 4 anemia was seen at $2.7\%$ of treatment cycles. Grade 3 or higher leucopenia was seen at $1.2\%$ of cycles. Grade 3 or 4 neutropenia and thrombocytopenia occurred at $6.1\%\;and\;1.5\%$ of cycles, respectively. The most common nonhematologic toxicity was proteinuria. Though no patients experienced grade 3 or 4 proteinuria, proteinuria was a considerable factor for this chemotherapy. Grade 3 or higher gastrointestinal toxicities were nausea and vomiting ($4.6\%$ of patients) and diarrhea ($1.5\%$ of patients). Grade 2 renal toxicity with elevation of serum creatinine was seen in $0.3\%$ of cycles, which is less than that of other platinum analogues. This study showed that combination therapy of heptaplatin and 5-FU have modest antitumor activity against advanced gastric cancer without severe renal toxicity.

• Journal of Pharmaceutical Investigation
• /
• v.37 no.3
• /
• pp.179-186
• /
• 2007

A simple, sensitive and selective liquid chromatographic/tandem mass spectrometric method (LC-MS/MS) was developed and validated for doxifluridine and 5-fluorouracil (5-FU) quantification in dog heparinized plasma. Sample preparation was based on liquid-liquid extraction using a mixture of isopropanol/ethyl acetate (1/9 v/v) to extract doxifluridine, 5-FU and 5-chlorouracil (5-CU, an internal standard) from plasma. Chromatography was performed on a C-18 analytical column and the retention times were 2.7, 1.5 and 1.7 min for doxifluridine, 5-FU and 5-CU, respectively with shorter analysis time within 5 min than previously reported methods. The ionization was optimized using ESI negative mode and selectivity was achieved by tandem mass spectrometric analysis by multiple reaction monitoring (MRM) using the transformations of m/z 244.8>107.6, 129.0>42.0 and 144.9>42.1 for doxifluridine, 5-FU and 5-CU, respectively. The achieved low limit of quantification was 20.0 ng/mL and the assay exhibited linear range of 20-2000 ng/mL ($R^2>0.99957$ for doxifluridine and $R^2>0.99857$ for 5-FU), using $100{\mu}L$ of plasma. Accuracy and precision of quality control samples for both doxifluridine and 5-FU met KFDA and FDA Guidance criteria of 15% for accuracy with coefficients of variation less than 15%. This method demonstrated adequate sensitivity, specificity, accuracy, precision and stability to support the simultaneous analysis of doxifluridine and 5-FU in dog plasma samples in pharmacokinetic and bioequivalence studies.